JP2024540922A - Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 - Google Patents

Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 Download PDF

Info

Publication number
JP2024540922A
JP2024540922A JP2024523525A JP2024523525A JP2024540922A JP 2024540922 A JP2024540922 A JP 2024540922A JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024523525 A JP2024523525 A JP 2024523525A JP 2024540922 A JP2024540922 A JP 2024540922A
Authority
JP
Japan
Prior art keywords
compound
crystalline form
peaks
xiv
form xiv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523525A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024540922A5 (https=
Inventor
アイ． ヴラホヴァ、ペティンカ
ネルソン、ジェニファー
トマス ブランドル、マイケル
センテシュ、エイドリアン
カズ、ゾルタン
デメテル、アーダーム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Richter Gedeon Nyrt
Original Assignee
Richter Gedeon Nyrt
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Richter Gedeon Nyrt filed Critical Richter Gedeon Nyrt
Publication of JP2024540922A publication Critical patent/JP2024540922A/ja
Publication of JP2024540922A5 publication Critical patent/JP2024540922A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024523525A 2021-10-18 2022-10-18 Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形 Pending JP2024540922A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163257073P 2021-10-18 2021-10-18
US63/257,073 2021-10-18
PCT/EP2022/078989 WO2023066941A1 (en) 2021-10-18 2022-10-18 Crystalline form of an ethanol solvate of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Publications (2)

Publication Number Publication Date
JP2024540922A true JP2024540922A (ja) 2024-11-06
JP2024540922A5 JP2024540922A5 (https=) 2025-10-27

Family

ID=84359608

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523525A Pending JP2024540922A (ja) 2021-10-18 2022-10-18 Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素のエタノール溶媒和物の結晶形

Country Status (5)

Country Link
US (1) US20250066382A1 (https=)
EP (1) EP4419530A1 (https=)
JP (1) JP2024540922A (https=)
CN (1) CN118451082A (https=)
WO (1) WO2023066941A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
BR112022023937A2 (pt) 2020-05-29 2022-12-27 Myovant Sciences Gmbh Formas de dosagem oral sólidas de combinação de antagonistas do hormônio liberador de gonadotropina

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1591446B1 (en) 2003-01-29 2013-03-06 Takeda Pharmaceutical Company Limited Thienopyrimidine compounds and use thereof
PL2900675T3 (pl) 2012-09-28 2019-08-30 Takeda Pharmaceutical Company Limited Sposób wytwarzania pochodnej tienopirymidyny
CA2978223A1 (en) 2015-02-26 2016-09-01 Takeda Pharmaceutical Company Limited Formulations of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethyl amino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
EP3518933B2 (en) 2016-09-30 2025-02-26 Sumitomo Pharma Switzerland GmbH Methods of treating uterine fibroids and endometriosis
CN110248661A (zh) 2016-09-30 2019-09-17 梦欧文科学有限责任公司 前列腺癌的治疗
WO2019178304A1 (en) * 2018-03-14 2019-09-19 Teva Pharmaceuticals International Gmbh Solid state forms of relugolix
JP2022551316A (ja) 2019-10-10 2022-12-08 ミオバント サイエンシズ ゲーエムベーハー Ｎ－（４－（１－（２，６－ジフルオロベンジル）－５－（（ジメチルアミノ）メチル）－３－（６－メトキシ－３－ピリダジニル）－２，４－ジオキソ－１，２，３，４－テトラヒドロチエノ［２，３－ｄ］ピリミジン－６－イル）フェニル）－Ｎ’－メトキシ尿素の結晶形
EP4041738A1 (en) 2019-10-10 2022-08-17 Myovant Sciences GmbH Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea

Also Published As

Publication number Publication date
CN118451082A (zh) 2024-08-06
WO2023066941A1 (en) 2023-04-27
US20250066382A1 (en) 2025-02-27
EP4419530A1 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
US20250066382A1 (en) Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5-((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
US12060367B2 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
RU2507202C2 (ru) Новые фенилпиразиноны в качестве ингибиторов киназы
EP4294799A2 (en) Compositions and methods for inhibition of ras
JP7358387B2 (ja) Ｍｔｏｒ阻害剤としてのｃ４０－、ｃ２８－およびｃ－３２－連結ラパマイシン類似体
JP4357295B2 (ja) ピラゾール誘導キナーゼインヒビターとその使用
JP5603869B2 (ja) 新規化合物
KR101060051B1 (ko) 비정상적인 세포 성장을 치료하기 위한 피리미딘 유도체
US20220372044A1 (en) Crystalline solvated forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo-1,2,3,4- tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'-methoxyurea
CA2332528A1 (en) Pyrrolo[1,2-b]pyridazine spla2 inhibitory
CA2445357A1 (en) Pyrazole derived kinase inhibitors
EP2581373A1 (en) Benzo- or pyrido-imidazole derivative
EP4041739A1 (en) Crystalline forms of n-(4-(1-(2,6-difluorobenzyl)-5- ((dimethylamino)methyl)-3-(6-methoxy-3-pyridazinyl)-2,4-dioxo- 1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl)phenyl)-n'- methoxyurea
US20230227470A1 (en) Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
CN113631163A (zh) 包括噻吩中心环的srebp抑制剂
RS20060196A (sr) Imidazopiridinski derivati kao inhibitori inducibilne no-sintaze
CN117751099A (zh) 酰胺类化合物及其应用
CN117157290A (zh) 用于抑制kras的组合物及方法
RU2805211C2 (ru) С40-, с28- и с-32-связанные аналоги рапамицина в качестве ингибиторов mtor
US3772283A (en) 3,5-androstadieno-(3,4-d)-2'-imino-3'-substituted)-thiazolines,isomers thereof,methods for their manufacture and intermediates useful therein
JP2025529992A (ja) ベンズイミダゾール系化合物、その調製方法および使用
KR20250127754A (ko) 에버멕틴 유도체
HK40104894A (zh) 用於抑制kras的组合物及方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240708

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20240708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240823

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251017

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017